All News

2018

June

Media Release / Jun 02, 2018

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

Read More
Media Release / Jun 01, 2018

Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion

Read More
Media Release / Jun 01, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab

Read More
Media Release / Jun 01, 2018

Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine

Read More

May

Media Release / May 30, 2018

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

Read More
T-cell with active receptors
Story / May 29, 2018

Immuno-oncology researchers seek to build smart drug combos

Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.

Read More
Media Release / May 28, 2018

Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

Read More
Media Release / May 24, 2018

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

Read More
Vice President of Strategic Data shares her story for “Women in Science.”
Story / May 18, 2018

Women in Science: Mimi Huizinga

Meet our Vice President of Strategic Data and Digital at Novartis Oncology.

Read More
Media Release / May 18, 2018

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More